Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology
NCT02140736 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2333
Last updated 2024-02-28
Summary
The main aim of this study is to observe correction of the hemoglobin level in the patients under chemotherapy, treated with epoetin alfa biosimilar and presenting with a solid tumor or a lymphoma or a myeloma.
Conditions
- Chemotherapy-induced Symptomatic Anemia
- Solid Tumors
- Malignant Hemopathies
- Lymphomas
- Myelomas
Interventions
- DRUG
-
Epoetin biosimilar
Sponsors & Collaborators
-
Hospira, now a wholly owned subsidiary of Pfizer
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-09-30
- Primary Completion
- 2011-08-31
- Completion
- 2011-08-01
Countries
- France
Study Locations
More Related Trials
-
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
NCT00003600 ·Status: COMPLETED ·Phase: PHASE3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
NCT00003341 ·Status: COMPLETED ·Phase: PHASE3
-
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
NCT01444456 ·Status: COMPLETED
-
A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy
NCT00216541 ·Status: COMPLETED ·Phase: PHASE4
-
Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors
NCT00875004 ·Status: TERMINATED ·Phase: NA
-
A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors
NCT02554942 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy
NCT02761642 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy
NCT00524407 ·Status: COMPLETED ·Phase: PHASE4
-
Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study
NCT02454530 ·Status: TERMINATED
-
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
NCT00338286 ·Status: COMPLETED ·Phase: PHASE3
-
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
NCT00070382 ·Status: COMPLETED ·Phase: PHASE3
-
Epoetin Beta in Treating Fatigue and Anemia in Patients Receiving Palliative Care for Malignant Solid Tumors
NCT00559195 ·Status: COMPLETED ·Phase: PHASE2
-
Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer
NCT00255749 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy
NCT00083486 ·Status: TERMINATED ·Phase: PHASE3
-
SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies
NCT06737081 ·Status: RECRUITING ·Phase: PHASE2
-
A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia
NCT01394991 ·Status: COMPLETED ·Phase: PHASE4
-
Dosing and Outcomes Study of Erythropoietic Stimulating Therapies in Patients With Chemotherapy Induced Anemia
NCT00212862 ·Status: COMPLETED
-
A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy Drug
NCT00269997 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy
NCT00283465 ·Status: COMPLETED ·Phase: PHASE4
-
Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy
NCT00210600 ·Status: COMPLETED ·Phase: PHASE2
-
Anemia in Patients With a Non-Myeloid Malignancy
NCT00038064 ·Status: COMPLETED ·Phase: PHASE3
-
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
NCT01459653 ·Status: COMPLETED
-
Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim
NCT01519700 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced
NCT00210002 ·Status: TERMINATED ·Phase: PHASE2
-
Trial to Compare the Efficacy and Safety of Pegfilgrastim Biosimilar in Subjects With High Risk Stage Breast Cancer Receiving Chemotherapy
NCT02768714 ·Status: WITHDRAWN ·Phase: PHASE3